



Docket No.: 1220(211111)  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Andrew Segal

Application No.: 09/345,148

Confirmation No.: 9870

Filed: June 30, 1999

Art Unit: 1644

For: CD40 LIGAND-ENHANCED CELLS AND  
METHODS OF MODULATING AN IMMUNE  
RESPONSE TO AN ANTIGEN

Examiner: P. Gambel

**RESPONSE TO RESTRICTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed January 26, 2007, Applicant hereby provisionally elects claims **Species B**: "a cell comprises the antigen and the cell is a *non-recombinant cell* and wherein the engineered ligand for CD40, which comprises a ligand for CD40 and a moiety heterologous to said ligand for CD40, wherein said moiety [that] binds to said cell is a *separate element but has been admixed* with the non-recombinant cell comprising an antigen and the cell, antigen and the engineered ligand and moiety are *all combined prior to administration*" for continued examination, with traverse.

A petition for extension of time is being filed herewith.

Dated: July 26, 2007

Respectfully submitted,

By   
Matthew Beaudet

Registration No.: 50,649  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 239-0614  
Attorneys/Agents For Applicant